Cipla Limited has announced the incorporation of a new wholly owned subsidiary in the Kingdom of Saudi Arabia, marking a strategic expansion into the Middle Eastern pharmaceutical market. The company informed stock exchanges on 2nd March, 2026, about the establishment of 'Cipla Middle East Company' effective 1st March, 2026.

Subsidiary Structure and Incorporation Details

The new subsidiary was incorporated by Cipla (EU) Limited, UK, which is itself a wholly owned subsidiary of Cipla Limited. This creates a step-down subsidiary structure for the company's Middle Eastern operations.

Business Objectives and Strategic Purpose

Cipla Middle East Company has been incorporated with specific objectives aligned with the pharmaceutical industry. The subsidiary will focus on:

• Manufacturing pharmaceutical products in Saudi Arabia
• Distribution of pharmaceutical products across the region
• Holding marketing authorizations in the Kingdom of Saudi Arabia

The establishment of this subsidiary represents Cipla's commitment to expanding its presence in the Middle Eastern pharmaceutical market and establishing local manufacturing capabilities.

Regulatory Compliance and Disclosure

The incorporation was disclosed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company provided comprehensive details as required by SEBI Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January, 2026.

Market Expansion Strategy

The incorporation of Cipla Middle East Company demonstrates the company's strategic approach to international expansion. By establishing a local entity in Saudi Arabia, Cipla positions itself to better serve the Middle Eastern pharmaceutical market while maintaining compliance with local regulatory requirements.

As a newly incorporated entity, the subsidiary currently has no applicable turnover or historical financial data. The focus remains on establishing operational capabilities and securing necessary regulatory approvals for pharmaceutical manufacturing and distribution activities in the Kingdom of Saudi Arabia.

Cipla Limited has notified stock exchanges about a revision in its Environmental, Social, and Governance (ESG) rating for the financial year 2024-25. The pharmaceutical company disclosed that NSE Sustainability Ratings & Analytics Limited, a SEBI registered ESG Rating Provider, has lowered the company's ESG rating from 66 to 65.

ESG Rating Revision Details

The rating revision was communicated through a formal intimation to multiple stock exchanges on 26th February, 2026, in compliance with Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company also referenced SEBI Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January, 2026 in its disclosure.

Potential Impact Factor

Cipla has indicated that the ESG rating revision is potentially due to a product recall by Cipla USA Inc., a wholly owned subsidiary of the company. This product recall occurred in January 2026, which appears to have influenced the rating assessment for the current financial year.

Regulatory Compliance

The disclosure was made to three key exchanges and regulatory bodies:

• BSE Limited (Scrip Code: 500087)
• National Stock Exchange of India Limited (Scrip Code: CIPLA)
• Societe de la Bourse de Luxembourg

The intimation was signed by Rajendra Chopra, Company Secretary, and digitally authenticated on 26th February, 2026 at 17:08:34 +05'30'. This formal communication ensures compliance with mandatory disclosure requirements for ESG rating changes under current regulatory frameworks.